Concord Biotech Limited (NSE:CONCORDBIO)
India · Delayed Price · Currency is INR 1,204.50
-17.50 (-1.43%)
Jan 28, 2026, 9:30 AM IST
Concord Biotech Revenue
Concord Biotech had revenue of 2.47B INR in the quarter ending September 30, 2025, a decrease of -20.35%. This brings the company's revenue in the last twelve months to 11.25B, up 3.63% year-over-year. In the fiscal year ending March 31, 2025, Concord Biotech had annual revenue of 12.00B with 18.01% growth.
Revenue (ttm)
11.25B
Revenue Growth
+3.63%
P/S Ratio
11.36
Revenue / Employee
7.16M
Employees
1,571
Market Cap
127.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12.00B | 1.83B | 18.01% |
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | 6.17B | 1.05B | 20.42% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 164.76B |
| Dishman Carbogen Amcis | 27.59B |
| Anthem Biosciences | 20.77B |
| OneSource Specialty Pharma | 14.19B |
| Blue Jet Healthcare | 11.79B |
| Supriya Lifescience | 7.15B |
| Panacea Biotec | 6.04B |
| Zota Health Care | 4.02B |